HC Wainwright & Co. Reiterates Buy on Kinnate Biopharma, Maintains $24 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Kinnate Biopharma (NASDAQ:KNTE) and maintained a $24 price target.
August 15, 2023 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Kinnate Biopharma and maintained a $24 price target.
The reiteration of a 'Buy' rating by HC Wainwright & Co. indicates their continued confidence in Kinnate Biopharma. The maintained price target of $24 suggests they believe the stock is still undervalued. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100